排序方式: 共有3条查询结果,搜索用时 15 毫秒
1
1.
Jos Antonio García-Espinoza Jos Francisco Muoz-Valle Mariel García-Chagolln Jorge Hernndez-Bello Claudia Azucena Palafox-Snchez Erika Fabiola Lpez-Villalobos Gabriela Athziri Snchez-Zuno Gloria Esther Martínez-Bonilla Sergio Cerpa-Cruz Francisco Josue Carrillo-Ballesteros Edith Oregon-Romero 《Current issues in molecular biology》2022,44(2):764
Background: Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease, which affects exocrine glands. T cell activation is a trigger mechanism in the immune response. Hyperreactivity of T cells and antibody production are features in pSS. ICOS can be critical in the pathogenesis of pSS. Methods: A total of 134 pSS patients and 134 control subjects (CS) were included. Genotyping was performed by PCR-RFLP. ICOS mRNA expression was quantified by real-time PCR, and CD4+ ICOS+ T cells were determined by flow cytometry. Results: The ICOS IVS1 + 173 T>C polymorphisms were not associated with susceptibility to pSS (p = 0.393, CI = 0.503–1.311). However, the c.1624 C>T polymorphism was associated with a reduction in the risk of development of pSS (p = 0.015, CI = 0.294–0.884). An increase in ICOS mRNA expression in patients was observed (3.7-fold). Furthermore, pSS patients showed an increase in membranal-ICOS expression (mICOS). High expression of mICOS (MFI) was associated with lymphocytic infiltration. Conclusions: The IVS1 + 173 polymorphism is not a genetic marker for the development of pSS, while c.1624 T allele was associated with a low risk. However, elevated mICOS expression in pSS patients with high lymphocytic infiltration was found. ICOS may have an important role in the immunopathogenesis of pSS and should be analyzed in T cell subsets in pSS patients as a possible disease marker. 相似文献
2.
Fernández-Torres Javier Zamudio-Cuevas Yessica López-Reyes Alberto Garrido-Rodríguez Daniela Martínez-Flores Karina Lozada Carlos Alberto Muñóz-Valle José Francisco Oregon-Romero Edith Martínez-Nava Gabriela Angélica 《Molecular biology reports》2018,45(5):1089-1098
Molecular Biology Reports - This study was designed to investigate whether genetic polymorphisms of the Wnt/β-catenin signaling pathway and its interactions are involved in the development of... 相似文献
3.
Monica Vázquez-Del Mercado Claudia A Palafox-Sánchez Jose F Muñoz-Valle Gerardo Orozco-Barocio Edith Oregon-Romero Rosa E Navarro-Hernández Mario Salazar-Páramo Juan Armendariz-Borunda Jorge I Gámez-Nava Laura Gonzalez-Lopez Jason YF Chan Edward KL Chan Minoru Satoh 《Arthritis research & therapy》2010,12(1):1-9
Introduction
Autoantibodies to RNA helicase A (RHA) were reported as a new serological marker of systemic lupus erythematosus (SLE) associated with early stage of the disease. Anti-RHA and other autoantibodies in Mexican SLE patients and their correlation with clinical and immunological features were examined.Methods
Autoantibodies in sera from 62 Mexican SLE patients were tested by immunoprecipitation of 35S-labeled K562 cell extract and enzyme-linked immunosorbent assay (anti-U1RNP/Sm, ribosomal P, β2GPI, and dsDNA). Anti-RHA was screened based on the immunoprecipitation of the 140-kDa protein, the identity of which was verified by Western blot using rabbit anti-RHA serum. Clinical and immunological characteristics of anti-RHA-positive patients were analyzed.Results
Anti-RHA was detected in 23% (14/62) of patients, a prevalence higher than that of anti-Sm (13%, 8/62). Prevalence and levels of various autoantibodies were not clearly different between anti-RHA (+) vs. (-) cases, although there was a trend of higher levels of anti-RHA antibodies in patients without anti-U1RNP/Sm (P = 0.07). Both anti-RHA and -Sm were common in cases within one year of diagnosis; however, the prevalence and levels of anti-RHA in patients years after diagnosis did not reduce dramatically, unlike a previous report in American patients. This suggests that the high prevalence of anti-RHA in Mexican patients may be due to relatively stable production of anti-RHA.Conclusions
Anti-RHA was detected at high prevalence in Mexican SLE patients. Detection of anti-RHA in races in which anti-Sm is not common should be clinically useful. Racial difference in the clinical significance of anti-RHA should be clarified in future studies. 相似文献
1